title: Patients with NASH and cryptogenic cirrhosis are less likely than those with hepatitis C to receive liver transplants.
abstract: OBJECTIVE
  Many patients with cryptogenic cirrhosis (CC) have other conditions associated with nonalcoholic steatohepatitis (NASH) that put them at risk for complications that preclude orthotopic liver transplantation (OLT).
  
  
  METHODS
  We followed all patients with NASH and CC who were evaluated for OLT (n = 218) at Baylor Simmons Transplant Institute between March 2002 and May 2008. Data were compared with those from patients evaluated for OLT because of hepatitis C virus (HCV)-associated cirrhosis (n = 646).
  
  
  RESULTS
  Patients with NASH and CC were older, more likely to be female, had a higher body mass index, and a greater prevalence of diabetes and hypertension, compared with patients with HCV-associated cirrhosis, but the 2 groups had similar model for end-stage liver disease (MELD) scores. NASH and CC in patients with MELD scores ≤15 were less likely to progress; these patients were less likely to receive OLT and more likely to die or be taken off the wait list because they were too sick, compared with patients with HCV-associated cirrhosis. The median progression rate among patients with NASH and CC was 1.3 MELD points per year versus 3.2 MELD points per year for the HCV group (P = .003). Among patients with MELD scores >15, there were no differences among groups in percentage that received transplants or rate of MELD score progression. Hepatocellular carcinoma occurred in 2.7% of patients with NASH and CC per year, compared with 4.7% per year among those with HCV-associated cirrhosis.
  
  
  CONCLUSIONS
  Patients with NASH and CC and low MELD scores have slower disease progression than patients with HCV-associated cirrhosis and are less likely to receive OLT.
authors.affiliation: Annette C. and Harold C. Simmons Transplant Institute, Baylor University Medical Center, Dallas, Texas, USA. jacquelo@baylorhealth.edu
authors.forename: Jacqueline G
authors.initials: JG
authors.lastname: O'Leary
authors.forename: Carmen
authors.initials: C
authors.lastname: Landaverde
authors.forename: Linda
authors.initials: L
authors.lastname: Jennings
authors.forename: Robert M
authors.initials: RM
authors.lastname: Goldstein
authors.forename: Gary L
authors.initials: GL
authors.lastname: Davis
mesh_terms: D018450:Disease Progression; D005234:Fatty Liver / Q000150:complications* / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D019698:Hepatitis C, Chronic / Q000150:complications* / Q000473:pathology; D006521:Hepatitis, Chronic / Q000150:complications* / Q000473:pathology; D006801:Humans; D008103:Liver Cirrhosis / Q000150:complications* / Q000473:pathology; D017093:Liver Failure / Q000453:epidemiology* / Q000601:surgery*; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D065626:Non-alcoholic Fatty Liver Disease; D012720:Severity of Illness Index